Drug Approval | December 26, 2025
Japan nod to Dupixent for children with severe asthma
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Subscribe To Our Newsletter & Stay Updated
